List view / Grid view
8 January 2018 | By Marc Princen - Allergan
Marc Princen, Executive Vice President and President Allergan International, explains how Allergan’s novel ethos and innovative approach makes it stand out from the crowd...
8 January 2018 | By Simon Pearce ( Thermo Fisher Scientific)
From the early use of Hansch parameters and Topliss Trees to today’s computational structure–activity techniques, medicinal chemists have long sought to rationalise drug design to find the quickest and most resource-efficient route to market. But while modern strategies are more reliant on statistical algorithms and vast data libraries, these founding…
5 January 2018 | By Dr Chris Barber (CEO Lhasa Limited)
The emergence of big data, technological innovations and advancements in scientific research is set to be transformative for the pharmaceutical industry, providing faster access to insights that can drive more informed decision making and accelerate drug development. Dr Chris Barber, CEO of Lhasa Limited, looks at what is next for…
5 January 2018 | By Marc-Antoine Lucchini - Sanofi
Sanofi has long been at the forefront of the drive to find new, innovative solutions for patients in different therapeutic areas, such as diabetes, cancer, cardiovascular diseases or rare diseases. Marc-Antoine Lucchini, SVP Diabetes and Cardiovascular Europe and Coordinator, Sanofi Europe, discusses some of the company’s achievements...
4 January 2018 | By David Elder (JPAG member and consultant)
Microbiological contamination of non-sterile medicinal products is an infrequent, but longstanding and recurring issue. But there is no ‘one size fits all’ approach towards objectionable organisms, says David Elder...
4 January 2018 | By Johan Devenyns, Johan Devenyns - PharmaFluidics
Much rests on the further development of bioanalytical technologies which allow the highest level of sensitivity on small samples, and robust, high reproducibility across large populations. Johan Devenyns, CEO PharmaFluidics, explains further...
4 January 2018 | By Dr Lynn Murdoch - Wickham Laboratories
When thinking about the future of the pharmaceutical sector, it can be difficult to pinpoint a specific focus as there are a wide range of challenges that come into consideration across all stages of development and manufacturing. Dr Lynne Murdoch, Business Manager – Microbiology, Wickham Laboratories, considers some key points....
4 January 2018 | By Olivier Laureau - CEO of Servier
Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. Olivier Laureau, CEO of Servier and President of the Fondation Internationale de Recherche Servier, explains the initiative and other achievements.
4 January 2018 | By Beatriz Faro - Pfizer
For Pfizer, putting patients first guides its actions, informs its strategic decisions and unifies colleagues in every region and function across the company. Beatriz Faro, Regional President, Internal Medicine, International Developed Markets at Pfizer, explains how the company’s philosophy is taking the business forward...
4 January 2018 | By Dr Sarfaraz K Niazi - Karyo Biologics
Since 2007, the EMA has approved 31 biosimilar products1 and refused or withdrawn around five. The FDA, however, since the enactment of the Biologics Price Competition and Innovation Act (BPCIA) in 2009,2 has licensed six products under PHS 351(k) of the Public Health Service (PHS) Act; approved one product under…
3 January 2018 | By Dave Elder, Gene Pacowski, Peter Nelson, Stephen Tindal
Particle size reduction is a fast and cost-effective answer to increasing the exposure of poorly soluble oral drugs by increasing surface area and thereby improving dissolution rate. This approach will only work for DCS IIa1 drugs where dissolution rate is the rate-limiting factor for absorption. This may be applicable to…
2 January 2018 | By Jos Corver, Pieter-Jan Van Bockstal, Thomas De Beer
Among the list of over 300 FDA and EMA approved biopharmaceutical products, around 50% are freeze-dried – indicating that freeze-drying is the preferred way of stabilising biopharmaceutical drug products that are unstable in aqueous solution, despite the high cost and long processing time linked to this manufacturing technique.1,2
2 January 2018 | By Henry Havel
At least some degree of solubility in water is necessary for active ingredients in pharmaceutical products to be effective in vivo. However, as efforts to discover and synthesise new active ingredients are pursued by industrial and academic medicinal chemists, achieving sufficient aqueous solubility can often be a significant limitation to…
2 January 2018 | By David Lovett, Furqan Tahir
Hot melt extrusion (HME), a manufacturing technique traditionally used in the plastic and food industries, is now attracting significant interest from the pharmaceutical manufacturing sector. This is primarily because HME enables the continuous manufacture of a wide variety of dosage formulations, including solid dose form, which is of particular importance…
2 January 2018 | By Christof Hohne
Christof Hohne, partner at patent law firm EIP, discusses second medical use claims and compulsory licences...
Send this to a friend
Follow: